daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Celltrion Inc (068270 KS)– Is the Sell-Side’s Bullishness Justified?

Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

Independent Insight Provider

Equity Bottom-Up

<ul>
<li>Celltrion Inc has significant underperformed over the last year and experienced a big derating.</li>
<li>Good results, but the numbers fell short of expectations due to the large biosimilar hype.</li>
<li>Outlook over the next five years is very promising, with its revenue target market value expected to almost double.  </li>
</ul>


Celltrion Inc has significant underperformed over the last year and experienced a big derating.
Good results, but the numbers fell short of expectations due to the large biosimilar hype.
Outlook over the next five years is very promising, with its revenue target market value expected to almost double.  


Celltrion Inc Update – Is It Time to Go Long (068270 KS)